GlassScriptPhysician profile
Edward I Marcus
NPI 1841451937
$153,275.03
in general payments reported to CMS, 2019-2025
32 companies · $35K in 2025
The $35K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $14K · 2021: $16K · 2022: $19K · 2023: $17K · 2024: $40K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Honoraria: $19K · Food and Beverage: $17K · Consulting Fee: $7,595 · Travel and Lodging: $1,847 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $400 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,560.59 |
| Honoraria | $19,094.00 |
| Food and Beverage | $17,167.34 |
| Consulting Fee | $7,594.50 |
| Travel and Lodging | $1,846.51 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $400.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $37,320.99 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $31,703.79 | 2019-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $25,636.91 | 2023-2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $9,231.86 | 2020-2025 | Acthar |
| Allergan, INC. | $8,026.66 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $7,493.89 | 2022-2025 | Xipere, Stellaris, Visudyne |
| Novartis Pharmaceuticals Corporation | $6,171.38 | 2019-2023 | |
| Apellis Pharmaceuticals, INC. | $5,856.70 | 2022-2025 | Syfovre |
| Eyepoint US, INC. | $5,497.78 | 2020-2023 | |
| Dutch Ophthalmic, USA | $3,331.34 | 2019-2025 | Tissueblue, Eva, Combined Machine |
| Novartis Pharma Ag | $2,925.00 | 2021 | |
| Ani Pharmaceuticals, INC. | $2,494.52 | 2024-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Harrow Eye, LLC | $2,401.17 | 2024-2025 | Iheezo, Triesence, Vevye |
| Abbvie INC. | $1,226.55 | 2022-2025 | |
| Genentech USA, INC. | $1,226.34 | 2021-2025 | Vabysmo, Susvimo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $663.30 | 2022-2024 | |
| Sandoz INC. | $565.00 | 2024-2025 | Cimerli |
| Biotissue Holdings INC. | $294.25 | 2022-2024 | |
| Alcon Vision LLC | $286.86 | 2022-2025 | Clareon, Eysuvis |
| Mallinckrodt Enterprises LLC | $237.76 | 2019 | |
| Biogen, INC. | $227.70 | 2022-2024 | Byooviz |
| Rxsight INC | $130.96 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Lensar, INC. | $100.52 | 2025 | Lensar Laser System |
| Horizon Therapeutics Plc | $71.61 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $38.95 | 2020-2024 | |
| Oyster Point Pharma, INC. | $38.40 | 2022-2023 | Tyrvaya |
| Samsara Vision | $28.78 | 2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
| Ocular Therapeutix, INC. | $24.81 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.75 | 2021 | |
| Notal Vision, INC. | $5.50 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.